Ontario's Life Sciences Commercialization Strategy
Ontario's $161-million Life Sciences Commercialization Strategy (PDF - 1.2MB) combines existing and new Ontario life sciences initiatives into a comprehensive and coordinated plan.
The province aims to be the best place in the world to take innovative bio-medical discoveries and turn them into new products and services that address unmet patient needs by capitalizing on world-class talent, research capacity and collaborative spirit.
The Life Sciences Commercialization Strategy has four fundamental pillars:
- Attracting and nurturing scientific excellence and talent
- Facilitating greater collaboration
- Addressing financing challenges, and
- Improving international marketing and promotion.
Several new and existing initiatives have been bundled as components to this new Strategy. Three key initiatives have been announced:
- Support to commercialize genomics research ($114.6-million GL² fund)
- Support for the medical and assistive devices sector ($21.4-million HTX-administered fund)
, and - Support for early stage Ontario biotechnology companies ($7-million MaRS-administered fund
For more information on the Strategy, please see Ontario's Life Sciences Commercialization Strategy (PDF - 1.2MB).
